These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Five-year follow-up after late conversion from calcineurin inhibitors to sirolimus in patients with chronic renal allograft dysfunction. Krüger B, Fischereder M, Jauch KW, Graeb C, Hoffmann U, Böger CA, Banas B, Obed A, Schlitt HJ, Krämer BK. Transplant Proc; 2007 Mar; 39(2):518-21. PubMed ID: 17362772 [Abstract] [Full Text] [Related]
11. Conversion to everolimus in kidney transplant recipients with decreased renal function. Inza A, Balda S, Alvarez E, Zárraga S, Gaínza FJ, Lampreabe I. Transplant Proc; 2009 Sep; 41(6):2134-6. PubMed ID: 19715854 [Abstract] [Full Text] [Related]
12. Calcineurin inhibitors, but not rapamycin, reduce percentages of CD4+CD25+FOXP3+ regulatory T cells in renal transplant recipients. Segundo DS, Ruiz JC, Izquierdo M, Fernández-Fresnedo G, Gómez-Alamillo C, Merino R, Benito MJ, Cacho E, Rodrigo E, Palomar R, López-Hoyos M, Arias M. Transplantation; 2006 Aug 27; 82(4):550-7. PubMed ID: 16926600 [Abstract] [Full Text] [Related]
14. Is sirolimus a safe alternative to reduce or eliminate calcineurin inhibitors in chronic allograft nephropathy in kidney transplantation? Lai WJ, Chiang YJ, Chen Y, Chu SH. Transplant Proc; 2004 Sep 27; 36(7):2056-7. PubMed ID: 15518744 [Abstract] [Full Text] [Related]
16. Conversion from a calcineurin inhibitor to everolimus therapy in maintenance liver transplant recipients: a prospective, randomized, multicenter trial. De Simone P, Metselaar HJ, Fischer L, Dumortier J, Boudjema K, Hardwigsen J, Rostaing L, De Carlis L, Saliba F, Nevens F. Liver Transpl; 2009 Oct 27; 15(10):1262-9. PubMed ID: 19790150 [Abstract] [Full Text] [Related]
17. Conversion from calcineurin inhibitor to sirolimus in pediatric chronic allograft nephropathy. Falger JC, Mueller T, Arbeiter K, Boehm M, Regele H, Balzar E, Aufricht C. Pediatr Transplant; 2006 Jun 27; 10(4):474-8. PubMed ID: 16712606 [Abstract] [Full Text] [Related]
18. A retrospective study of conversion from tacrolimus-based to sirolimus-based immunosuppression in orthotopic liver transplant recipients. Yu S, He X, Yang L, Ma Y, Zhu X, Ju W, Huang J. Exp Clin Transplant; 2008 Jun 27; 6(2):113-7. PubMed ID: 18816237 [Abstract] [Full Text] [Related]
19. A randomized controlled trial of late conversion from calcineurin inhibitor (CNI)-based to sirolimus-based immunosuppression in liver transplant recipients with impaired renal function. Watson CJ, Gimson AE, Alexander GJ, Allison ME, Gibbs P, Smith JC, Palmer CR, Bradley JA. Liver Transpl; 2007 Dec 27; 13(12):1694-702. PubMed ID: 18044728 [Abstract] [Full Text] [Related]
20. Excellent long-term results in de novo renal transplant recipients treated with proliferation signal inhibitors and reduced calcineurin inhibitors exposure. Carmellini M, Collini A, Ruggieri G, Garosi G, Bernini M. Transplant Proc; 2008 Dec 27; 40(6):1858-61. PubMed ID: 18675070 [Abstract] [Full Text] [Related] Page: [Next] [New Search]